Gene Therapy: Navigating Challenges & The Path to Future Investment
The promise of gene therapies – offering potential one-time cures for debilitating genetic diseases – is facing a critical juncture. While more than 50 gene therapies have now gained global approval, and innovative approaches like personalized gene editing are showing remarkable early success, a recent analysis reveals a concerning trend: a decline in the total number of gene therapies in active development. Maintaining momentum in this field requires sustained investment, transparent data sharing, and adaptable regulatory frameworks.
Personalized Gene Editing: A Breakthrough Moment
The field recently celebrated a landmark achievement with the rapid development of a personalized gene-editing therapy to save a newborn suffering from a severe metabolic disorder1. This success, alongside the first published clinical report of prime editing – a more precise gene editing technique – in patients with immunodeficiency2, demonstrates the accelerating potential of these technologies. Prime editing offers a potentially more accurate way to correct genetic defects compared to earlier CRISPR-based methods, minimizing unintended edits.
A Shift in the Landscape: Declining Development Pipelines
Despite these advancements, the American Society for Gene & Cell Therapies (ASGCT) recently reported a reversal in the upward trend of gene therapy development. Their 2025 landscape analysis indicates that while more therapies are reaching late-stage clinical trials, the overall number in active development has decreased3. This decline is attributed to a combination of factors, including a pullback from early-stage preclinical research and restructuring within biotech and pharmaceutical companies, leading to research program terminations and layoffs.
Safety Concerns and Clinical Holds
The past year has also been marked by safety concerns that have temporarily stalled progress. Trials were put on hold in 2025 following deaths of patients receiving gene therapy for Duchenne muscular dystrophy and, separately, a CRISPR-based therapy for amyloidosis. You can find more information about the FDA’s investigation into the Duchenne muscular dystrophy cases here. These events underscore the critical necessitate for rigorous safety monitoring and transparent reporting of adverse events in gene therapy trials.
Manufacturing Costs and Market Access
Beyond safety, economic hurdles are also impacting the field. Pfizer recently discontinued its gene therapy for hemophilia B, Beqvez, less than a year after its approval, citing high manufacturing costs and limited uptake4. The high cost of developing and manufacturing these therapies, coupled with challenges in demonstrating cost-effectiveness, can limit patient access and hinder long-term sustainability.
FDA’s Evolving Regulatory Approach
The regulatory landscape in the United States has been particularly dynamic. In late 2025, the FDA announced new guidance aimed at streamlining the approval process for cell and gene therapies, including a potential pathway for personalized gene-editing therapies6. This guidance proposes greater flexibility and potentially lower data requirements for approval. However, some experts caution that this approach could introduce increased risks. The FDA’s move contrasts with the more cautious approach of the European Medicines Agency, which often relies on conditional approval pathways. You can read more about the FDA’s new guidance here.
Global Perspectives: China’s Rising Role
While the US and Europe navigate evolving regulatory frameworks, China is emerging as a significant player in gene therapy development. Currently, China has approved nine CAR T-cell therapies and one gene therapy for hemophilia B. New National Medical Products Administration guidelines, slated to take effect in spring 2026, are designed to accelerate the review and approval process for innovative drugs, potentially boosting investment and growth in the sector.
The Importance of Data Sharing and Transparency
A critical element for continued progress is the transparent sharing of data, including results from trials that are terminated early. First-in-human trials are crucial for identifying safety signals, and timely reporting is paramount. Unfortunately, data from many terminated trials are not publicly available, representing a lost opportunity to learn and improve future gene therapy development. New standardized approaches for reporting safety signals are urgently needed.
Academic-Industry Collaboration and Non-Profit Innovation
Innovative models for collaboration are also emerging. A recent milestone was the FDA approval of a gene therapy developed by a non-profit organization in partnership with academic groups7, demonstrating the potential of alternative funding and development pathways.
Looking Ahead: Sustaining Momentum
The field of genetic therapies has historically weathered periods of both excitement and setbacks. To ensure continued progress, sustained investment in preclinical research, robust and predictable regulatory pathways, and a commitment to transparency and collaboration are essential. The recent challenges highlight the need for a holistic approach that addresses not only scientific innovation but also economic viability and patient safety. The FDA’s evolving guidance, coupled with increasing activity in China, suggests a dynamic future for gene therapies, but realizing the full potential of these groundbreaking treatments will require a concerted effort from all stakeholders.
What’s next for regulatory oversight? The FDA and other regulatory bodies will continue to refine their approval pathways based on emerging data and experience. Ongoing monitoring of approved therapies and continued investment in research to address safety concerns will be crucial.